{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:20:18Z","timestamp":1771266018960,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,3,20]],"date-time":"2015-03-20T00:00:00Z","timestamp":1426809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s00198-015-3100-7","type":"journal-article","created":{"date-parts":[[2015,3,19]],"date-time":"2015-03-19T12:21:18Z","timestamp":1426767678000},"page":"1857-1864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial"],"prefix":"10.1007","volume":"26","author":[{"given":"S. L.","family":"Greenspan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. T.","family":"Vujevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Brufsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. C.","family":"Lembersky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. J.","family":"van Londen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. C.","family":"Jankowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. L.","family":"Puhalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Perera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,20]]},"reference":[{"issue":"9","key":"3100_CR1","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1111\/j.1532-5415.2012.04107.x","volume":"60","author":"T Becker","year":"2012","unstructured":"Becker T, Lipscombe L, Narod S, Simmons C, Anderson GM, Rochon PA (2012) Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer. J Am Geriatr Soc 60(9):1761\u20131767. doi: 10.1111\/j.1532-5415.2012.04107.x","journal-title":"J Am Geriatr Soc"},{"key":"3100_CR2","first-page":"91","volume":"4","author":"M Bauer","year":"2012","unstructured":"Bauer M, Bryce J, Hadji P (2012) Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer. Breast Cancer (Dove Medical Press) 4:91\u2013101. doi: 10.2147\/bctt.s29432","journal-title":"Breast Cancer (Dove Medical Press)"},{"issue":"5","key":"3100_CR3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000321426","volume":"5","author":"P Hadji","year":"2010","unstructured":"Hadji P (2010) Guidelines for osteoprotection in breast cancer patients on an aromatase inhibitor. Breast Care (Basel, Switzerland) 5(5):290\u2013296. doi: 10.1159\/000321426","journal-title":"Breast Care (Basel, Switzerland)"},{"issue":"16","key":"3100_CR4","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1200\/JCO.2007.15.2967","volume":"26","author":"SL Greenspan","year":"2008","unstructured":"Greenspan SL, Brufsky A, Lembersky BC, Bhattacharya R, Vujevich KT, Perera S et al (2008) Risedronate prevents bone loss in breast cancer survivors: a 2 year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 26(16):2644\u20132652. doi: 10.1200\/JCO.2007.15.2967","journal-title":"J Clin Oncol"},{"issue":"5","key":"3100_CR5","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","volume":"118","author":"AM Brufsky","year":"2012","unstructured":"Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C et al (2012) Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 118(5):1192\u20131201. doi: 10.1002\/cncr.26313","journal-title":"Cancer"},{"issue":"1","key":"3100_CR6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clbc.2011.08.002","volume":"12","author":"A Llombart","year":"2012","unstructured":"Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J et al (2012) Immediate Administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 12(1):40\u201348. doi: 10.1016\/j.clbc.2011.08.002","journal-title":"Clin Breast Cancer"},{"issue":"9","key":"3100_CR7","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","volume":"9","author":"M Gnant","year":"2008","unstructured":"Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kassmann H, Piswanger-Solkner JC et al (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9(9):840\u2013849. doi: 10.1016\/s1470-2045(08)70204-3","journal-title":"Lancet Oncol"},{"issue":"6","key":"3100_CR8","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","volume":"28","author":"C Poznak Van","year":"2010","unstructured":"Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G et al (2010) Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 28(6):967\u2013975. doi: 10.1200\/jco.2009.24.5902","journal-title":"J Clin Oncol"},{"issue":"9","key":"3100_CR9","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00432-012-1233-z","volume":"138","author":"C Markopoulos","year":"2012","unstructured":"Markopoulos C, Tzoracoleftherakis E, Koukouras D, Venizelos B, Zobolas V, Misitzis J et al (2012) Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. J Cancer Res Clin Oncol 138(9):1569\u20131577. doi: 10.1007\/s00432-012-1233-z","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"3100_CR10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/bcr2584","volume":"12","author":"C Poznak Van","year":"2010","unstructured":"Van Poznak C (2010) Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition. Breast Cancer Res 12(3):110. doi: 10.1186\/bcr2584","journal-title":"Breast Cancer Res"},{"issue":"2","key":"3100_CR11","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1186\/bcr2565","volume":"12","author":"C Markopoulos","year":"2010","unstructured":"Markopoulos C, Tzoracoleftherakis E, Polychronis A, Venizelos B, Dafni U, Xepapadakis G et al (2010) Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res 12(2):R24. doi: 10.1186\/bcr2565","journal-title":"Breast Cancer Res"},{"issue":"13","key":"3100_CR12","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S1470-2045(14)71035-6","volume":"15","author":"I Sestak","year":"2014","unstructured":"Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F et al (2014) Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncol 15(13):1460\u20131468. doi: 10.1016\/s1470-2045(14)71035-6","journal-title":"Lancet Oncol"},{"issue":"4","key":"3100_CR13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00774-011-0341-1","volume":"30","author":"G Sergi","year":"2012","unstructured":"Sergi G, Pintore G, Falci C, Veronese N, Berton L, Perissinotto E et al (2012) Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. J Bone Miner Metab 30(4):461\u2013467. doi: 10.1007\/s00774-011-0341-1","journal-title":"J Bone Miner Metab"},{"issue":"19","key":"3100_CR14","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","volume":"14","author":"JE Lester","year":"2008","unstructured":"Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R et al (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14(19):6336\u20136342. doi: 10.1158\/1078-0432.ccr-07-5101","journal-title":"Clin Cancer Res"},{"issue":"9","key":"3100_CR15","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1200\/JCO.2011.38.0261","volume":"30","author":"NL Henry","year":"2012","unstructured":"Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S et al (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30(9):936\u2013942. doi: 10.1200\/jco.2011.38.0261","journal-title":"J Clin Oncol"},{"issue":"1","key":"3100_CR16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10549-009-0692-7","volume":"120","author":"K Briot","year":"2010","unstructured":"Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C (2010) Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat 120(1):127\u2013134. doi: 10.1007\/s10549-009-0692-7","journal-title":"Breast Cancer Res Treat"},{"key":"3100_CR17","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/ajcn\/46.4.685","volume":"46","author":"B Dawson-Hughes","year":"1987","unstructured":"Dawson-Hughes B, Jacques P, Shipp C (1987) Dietary calcium intake and bone loss from the spine in healthy postmenopausal women. Am J Clin Nutr 46:685\u2013687","journal-title":"Am J Clin Nutr"},{"key":"3100_CR18","unstructured":"Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Ross AC, Taylor CL, Yaktine AL, Del Valle HB (eds) (2011) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC)"},{"issue":"10","key":"3100_CR19","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S et al (2014) Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 25(10):2359\u20132381. doi: 10.1007\/s00198-014-2794-2","journal-title":"Osteoporos Int"},{"key":"3100_CR20","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/BF01622200","volume":"4","author":"JA Kanis","year":"1994","unstructured":"Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 4:368\u2013381","journal-title":"Osteoporos Int"},{"key":"3100_CR21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1385\/JCD:2:3:275","volume":"2","author":"LF Varney","year":"1999","unstructured":"Varney LF, Parker RA, Vincelette A, Greenspan SL (1999) Classification of osteoporosis and osteopenia in postmenopausal women is dependent on site-specific analysis. J Clin Densitom 2:275\u2013283","journal-title":"J Clin Densitom"},{"key":"3100_CR22","unstructured":"Coleman RE, Banks LM, Girgis SI, Vrdoljak E, Fox J, Porter LS, et al (2005) Skeletal effect of exemestane in the Intergroup Exemestane Study (IES) 2 year bone mineral density (BMD) and bone biomarker data. Presented at 28th Annual San Antonio Breast Cancer Symposium"},{"key":"3100_CR23","unstructured":"Howell A (2003) Effect of anastrozole on bone mineral density: 2-year results of the 'Arimidex' (anastrozole), Tamoxifen, Alone or in Combination (ATAC) trial. Presented at the San Antonio Breast Cancer Symposium 2003"},{"key":"3100_CR24","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1200\/JCO.2005.07.097","volume":"23","author":"PE Lonning","year":"2005","unstructured":"Lonning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI et al (2005) Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23:5126\u20135137","journal-title":"J Clin Oncol"},{"key":"3100_CR25","doi-asserted-by":"crossref","unstructured":"Brufsky A, Harker W, Beck J, Carroll R, Tan-Chiu E, Seidler C, et al (2005) Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): 12 mos BMD results of the Z-FAST trial. Presented at the annual meeting of the American Society of Clinical Oncology (ASCO)","DOI":"10.1200\/jco.2005.23.16_suppl.533"},{"key":"3100_CR26","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple imputation for nonresponse in surveys","author":"DB Rubin","year":"1987","unstructured":"Rubin DB (1987) Multiple imputation for nonresponse in surveys. John Wiley & Sons, Ltd., New York, NY"},{"issue":"2","key":"3100_CR27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","volume":"9","author":"AM Brufsky","year":"2009","unstructured":"Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC et al (2009) Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9(2):77\u201385. doi: 10.3816\/CBC.2009.n.015","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"3100_CR28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1634\/theoncologist.2012-0261","volume":"18","author":"A Valachis","year":"2013","unstructured":"Valachis A, Polyzos NP, Coleman RE, Gnant M, Eidtmann H, Brufsky AM et al (2013) Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist 18(4):353\u2013361. doi: 10.1634\/theoncologist.2012-0261","journal-title":"Oncologist"},{"issue":"4","key":"3100_CR29","doi-asserted-by":"crossref","first-page":"R183","DOI":"10.1530\/ERC-13-0099","volume":"20","author":"PE Lonning","year":"2013","unstructured":"Lonning PE, Eikesdal HP (2013) Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocr Relat Cancer 20(4):R183\u2013R201. doi: 10.1530\/erc-13-0099","journal-title":"Endocr Relat Cancer"},{"key":"3100_CR30","author":"A Mathew","year":"2014","unstructured":"Mathew A, Brufsky A (2014) Bisphosphonates in breast cancer. Int J Cancer. doi: 10.1002\/ijc.28965","journal-title":"Int J Cancer"},{"issue":"1","key":"3100_CR31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-009-0352-y","volume":"118","author":"GK Ellis","year":"2009","unstructured":"Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Fan M et al (2009) Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat 118(1):81\u201387. doi: 10.1007\/s10549-009-0352-y","journal-title":"Breast Cancer Res Treat"},{"issue":"30","key":"3100_CR32","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","volume":"26","author":"GK Ellis","year":"2008","unstructured":"Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26(30):4875\u20134882. doi: 10.1200\/jco.2008.16.3832","journal-title":"J Clin Oncol"},{"key":"3100_CR33","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1359\/jbmr.1998.13.9.1431","volume":"13","author":"SL Greenspan","year":"1998","unstructured":"Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB (1998) Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 13:1431\u20131438","journal-title":"J Bone Miner Res"},{"key":"3100_CR34","first-page":"3537","volume":"85","author":"SL Greenspan","year":"2000","unstructured":"Greenspan SL, Rosen HN, Parker RA (2000) Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 85:3537\u20133540","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3100-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-015-3100-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3100-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:48:44Z","timestamp":1566434924000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-015-3100-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,20]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["3100"],"URL":"https:\/\/doi.org\/10.1007\/s00198-015-3100-7","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,20]]}}}